||EPS - Basic
||Market Cap (m)
|Sarossa Daily Update: Sarossa is listed in the General Financial sector of the London Stock Exchange with ticker SARS. The last closing price for Sarossa was 1.52p.|
Sarossa has a 4 week average price of - and a 12 week average price of -.
The 1 year high share price is - while the 1 year low share price is currently -.
There are currently 464,758,478 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Sarossa is £7,064,328.87.
|johnsmith321: SARS price ticking up to 1.8p. With only 100M shares. I agree that NAV is down at the moment, but I think PHC and SLN will go back up to 100p and 300p soon.
No yield for GVC for the first year as with the last acquisition. The acquisition should stop GVC being dependent on any single source for more 10% earnings. In addition the move up to the main market should be positive for the share price. They also promised to maintain same rate of dividend once acquisition is completed.|
|johnsmith321: Hi Callumross,
Getting rid of the Abbvie pref shares made sense. As you say, they just cloud the investment picture.
NAV up, investments up and profits up (if you exclude the one of Biotech legacy refund). Yet the share price has not moved. There must be a large share overhang. I do not care how they do it, but they should get the share price to 2p at least (as NAV per share is 3.35p). Perhaps they need to consolidate the shares 1:100 and get away from the penny share label.
I like their follow on GVC investment (10% yield) should help to keep the NAV increasing year on year.|
|johnsmith321: Lets hope the next 48m shares does something to the share price :). They still have some cash. So they can continue buying back more shares. At some point the share price has to move.|
|johnsmith321: I was a bit disappointed that they bought so much. I was hoping they would do a little over a long time to make a constant demand for the stock. In addition, they would also make more news/publicity from buy back. I hope they also do a share consolidation after the buy back. Drag the company out of the penny stock label and into the respectable >£1 range. Perhaps then more funds may become interested.
Would be nice to see 3.2p, the share price has not really moved despite the constant increase in NAV. This is a investment that is taking longer to mature, than I had hoped.|
|smellsnbells: The initial SARS exitement took place on the OMH thread. Osmetech sold a few SARS `sniffers` to China and the share price took off out of all proportion to reality. With the epidemic seemingly now contained it should see a price ajustment this week downward and a major world wide out break of death will not now materialise.|
Sarossa share price data is direct from the London Stock Exchange